Zealand Hit With CRL for Ultrarare Genetic Disease Treatment
The rejection is related to the timing of the FDA’s reinspection of Zealand’s third-party manufacturer, which previously had deficiencies.
Zealand Hit With CRL for Ultrarare Genetic Disease Treatment Read More »
